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Abstract 
Review on PCSK4, with data on DNA/RNA, on the 
protein encoded and where the gene is implicated. 
Identity 
Other names: PC4, SPC5 
HGNC (Hugo): PCSK4 
Location: 19p13.3 
DNA/RNA 
Description 
This gene can be found on chromosome 19 at 
location: at 1432427 and ends at 1441410. 
Transcription 
The DNA sequence contains 15 exons and the 
transcript length: 2661 bps translated to a 755 
residues protein. 
Protein 
Description 
PCSK4 is a member of the family of subtilisin-like 
proprotein convertase (PCs) that process protein at 
basic residues.  
This protein is produced in the inactive zymogen 
form and is activated by proteolytic removal of its 
prodomain in the N-terminal site. 
Expression 
PCSK4 is restricted to the reproductive tract and 
expressed primarily in testicular germ cells and 
sperm.  
Low levels of PCSK4 mRNA have also been 
detected in ovaries and the placenta. 
Localisation 
PCSK4 exact intracellular location has not yet been 
determined. 
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Function 
PCSK4 cleaves synthetic peptide substrates after an 
Arg in a basic sequence context; most often after 
paired basic residues (K/R-X-K/R), to release 
mature proteins from their proproteins. PCSK4 
substrates include growth factors (DEAF-1, 
proIGF2, proenkephalin, proNGF, proPACAP, 
HGFR), receptors (IGF-1R, HGFR), and members 
of the ADAM (a-disintegrin-and-metalloproteinase) 
family (ADAM-1, ADAM-2, ADAM-3, ADAM-5). 
The activation/inactivation of these substrates 
implicated directly the latter to the regulation of 
gonadal functions, sperm motility, and species 
specific reproduction. 
Homology 
The PCSK4 catalytic domain has a high percentage 
of homology with those of the other PCs: 70% 
between PCSK4 and Furin. 
Implicated in 
Pregnancy difficulties 
Note 
An aberrant processing of IGF-II by PCSK4 plays a 
role in inadequate trophoblast migration and, thus, 
fetal growth restriction. 
Infertility 
Note 
The fertilizing ability of PCSK4 null spermatozoa 
was also found to be significantly reduced. 
Moreover, PCSK4 cleavages lead to sperm 
acquisition of fertilization competence. 
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